State Street Health Care Select Sector SPDR ETF

XLV

Market cap $40.6B

State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm's Q3 2026 sector outlook upgraded healthcare from neutral to positive.

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.

As the Q2 earnings season kicks off, the market is widely anticipating strong results, with the technology and energy sectors expected to lead the charge. Current analyst expectations point to a robust 23.3% earnings growth for the S&P 500, which would mark the second consecutive quarter of over 20% growth, according to FactSet.

State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech industry but has experienced higher volatility and a deeper maximum drawdown State Street Health Care Select Sector SPDR ETF tracks a broader index of 60 healthcare stocks from the S&P 500 compared to the Invesco fund's 253 biotech holdings

Traditionally speaking, folks that have looked to tap into innovation in the AI space have done so through tech exposure, particularly with mega-cap names. This is not a surprise, considering the interplay between these companies and AI innovation.

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

Weak June jobs growth boosts hopes of a dovish Fed, putting healthcare, tech, gold and emerging market ETFs in the spotlight.

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and far greater assets under management than Invesco Pharmaceuticals ETF. Invesco's ETF focuses exclusively on 29 pharmaceutical companies, whereas the SPDR fund provides broader exposure across the healthcare sector.